The available evidence from preclinical studies and clinical studies showed that the SGLT2 inhibitors have distinctive morbidity and mortality reduction benefits in patients with type 2 diabetes mellitus (T2DM) and heart failure (HF). The gene discussed is SLC5A2; the disease is heart failure.